Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Avanos Medical ( (AVNS) ).
On October 21, 2025, Avanos Medical announced the elimination of the Chief Commercial Officer and General Counsel positions as part of a broader organizational restructuring, effective December 1, 2025. This decision affects Kerr Holbrook and Mojirade James, who will receive severance packages and other benefits under the company’s Severance Pay Plan. The restructuring aims to reallocate responsibilities among other employees, potentially impacting the company’s operational dynamics and stakeholder interests.
The most recent analyst rating on (AVNS) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.
Spark’s Take on AVNS Stock
According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.
Avanos Medical’s overall stock score is primarily impacted by its financial performance and valuation concerns. Despite strong revenue growth, profitability challenges and a negative P/E ratio weigh heavily on the score. Technical analysis provides mixed signals, with potential resistance and bearish momentum. The earnings call, while positive in some areas, highlighted significant challenges, but was excluded from the score calculation.
To see Spark’s full report on AVNS stock, click here.
More about Avanos Medical
Avanos Medical, Inc. operates in the medical technology industry, focusing on providing innovative healthcare solutions. The company specializes in medical devices and products aimed at enhancing patient care and improving clinical outcomes.
Average Trading Volume: 632,132
Technical Sentiment Signal: Sell
Current Market Cap: $537.8M
See more insights into AVNS stock on TipRanks’ Stock Analysis page.